Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is
the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL)
following relapse of the disease. Although many people are cured of their lymphoma with this
therapy, the disease comes back in a certain proportion of patients. The purpose of this
study is to test the safety and effectiveness of the monoclonal antibody, CT-011, in patients
with DLBCL who have received autologous peripheral blood stem cell transplantation. All final
eligible patients will receive an IV infusion of CT-011 on Day 1 (30 to 90 days post
autologous PBSCT). Treatment will be repeated every 42 days for a total of three courses with
treatment visits on Days 1, 43, and 85. Follow-up for safety and clinical outcome will be
conducted throughout the study till 18 months post autologous PBSCT. Approximately 70
patients will participate in this study.